|
| |
Medicinal Marijuana Effective For Neuropathic Pain In HIV
Aug 07, 2008 -- In a double-blind, placebo-controlled clinical trial to assess the impact of smoked medical cannabis, or marijuana, on the neuropathic pain associated with HIV, researchers at the University of California, San Diego School of Medicine found that reported pain relief was greater with cannabis than with a placebo.
|
Molecule CX717 Has Positive Effects In Opiate-Induced Respiratory Depression In A Phase IIa Clinical Study
Aug 07, 2008 -- Cortex Pharmaceuticals, Inc. (AMEX: COR - News) reported that top-line data from its first Phase IIa study in opiate-induced respiratory depression (RD) demonstrated that a single oral dose of 2100mg of AMPAKINE® CX717 achieved statistical significance over placebo on the primary endpoint measure.
|
Pain Mediation By Innocuous Sensory Afferents
Aug 06, 2008 -- Expression of protein kinase Cγ (PKCγ) in interneurons of lamina II of the spinal cord dorsal horn is thought to be essential for mechanical allodynia, a painful response to normally innocuous stimuli. Nonpeptidergic nociceptors were initially assumed to innervate PKCγ interneurons, because they terminate in the same sublamina. Neumann et al. now show that the terminals of nonpeptidergic nociceptor afferents terminate dorsal to the PKCγ interneurons, with only minimal overlap.
|
FDA Accepts Streamlined Phase 3 Development Plan For Q8003IR 'Dual Opioid' Pain Therapy
Aug 06, 2008 -- QRxPharma Limited (ASX: QRX; OTCQX: QRXPY), a clinical-stage specialty pharmaceutical company focused on the development and commercialization of therapies for pain and central nervous system (CNS) disorders, announced today that the U.S.
|
Cara Therapeutics Announces Successful Completion Of Phase I Clinical Trial Of Novel Analgesic, CR845
Aug 06, 2008 -- Cara Therapeutics, Inc. announced completion of a Phase I clinical trial for its second-generation, peripherally acting kappa opioid agonist, CR845, under development for the treatment of acute and chronic pain. The drug candidate was safe and well-tolerated after intravenous infusion, and resulted in plasma levels of CR845 expected to be associated with clinical analgesic activity.
|
FDA Rejects Schering-Plough's Anaesthetic Drug Sugammadex NDA
Aug 05, 2008 -- The U.S. FDA has issued a non-approvable letter to Schering-Plough regarding the U.S. firm's New Drug Application (NDA) for sugammadex sodium. The product (also marketed under the brand Bridion) is a selective relaxant binding agent that reverses the effects of neuromuscular blockade by rocuronium in general anaesthesia. In a press statement, Schering-Plough has said that the FDA's concerns over the drug are related to hypersensitivity or allergic reactions.
|
Orthokine Treatment Is Effective For Knee Arthritis, Even After Two Years - Long-Study Confirms Effectiveness Of Autologous Therapy
Aug 05, 2008 -- The results of a two-year representative study of osteoarthritis of the knee, published in the internationally renowned journal "Osteoarthritis and Cartilage", confirm the safety and effectiveness of Orthokine therapy, in which anti inflammatory proteins obtained from the patient's own blood are injected into the arthritic joint.
|
U.S. FDA Issues Action Letter For Sugammadex
Aug 02, 2008 -- Schering-Plough Corporation (NYSE: SGP) announced that the U.S. Food and Drug Administration (FDA) has issued a "not-approvable" letter for sugammadex sodium injection for the reversal of muscle relaxation during general anesthesia.
|
Self-Repairing Cartilage? OHSU Research Reveals Important Clues
Aug 01, 2008 -- A strain of mice with the natural ability to repair damaged cartilage may one day lead to significant improvements in treatment of human knee, shoulder and hip injuries. Researchers at Oregon Health & Science University have discovered males from a strain of mice called MRL/MpJ have the innate ability to repair their own knee cartilage. "We think there is something special about these mice," said Jamie Fitzgerald, Ph.D.
|
UCB Receives Not-Approvable Letter From FDA For Lacosamide For Diabetic Neuropathic Pain
Jul 31, 2008 -- UCB announced that it received a not-approvable letter from the U.S. Food and Drug Administration (FDA) for lacosamide for the treatment of diabetic neuropathic pain in adults. The company will seek clarification from the FDA of its position and of the additional information required to obtain final marketing approval.
|
|